Clinical trial
A Phase 1b, Open Label Study of the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of 100 mg Clemizole Hydrochloride Administered Orally Twice a Day for 28 Days Immediately Prior to Initiation of Treatment With HCV Standard of Care Therapy in Treatment-Naïve Subjects Chronically Infected With HCV
NCT00945880 is registered in ClinicalTrials.gov with Eiger BioPharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Open Label Study of the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of 100 mg Clemizole Hydrochloride Administered Orally Twice a Day for 28 Days Immediately Prior to Initiation of Treatment With HCV Standard of Care Therapy in Treatment-Naïve Subjects Chronically Infected With HCV
- Lead sponsor
- Eiger BioPharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2009
- Completion date
- August 31, 2010
- Enrollment
- 12 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.